Psilocybin Assisted Psychotherapy for Depression and Drug Addiction

This trial tests whether a single dose of psilocybin, combined with therapy, can safely treat depression and drug addiction in veterans and first responders. Researchers will administer one of three psilocybin doses (5mg, 10mg, or 25mg) to participants to observe its effects on depression and substance use over six weeks. They also aim to understand how psilocybin impacts the brain. Veterans or first responders with treatment-resistant depression and substance use issues may be suitable candidates. As a Phase 1 and Phase 2 trial, this study seeks to understand how the treatment works and measure its effectiveness in an initial group, offering participants a chance to contribute to groundbreaking research.

You may not need to stop your current medications if they are not contraindicated (unsafe to use) with psilocybin and your dose has been stable for 6 months. The study physician will determine if your medications are safe to continue.

Research has shown that psilocybin, when combined with therapy, is generally safe for most people. A study of 117 individuals, many with serious illnesses, found that psilocybin with therapy may be safe. Some studies have reported side effects, usually mild or moderate, while serious side effects remain rare.

Another study involving individuals with Alcohol Use Disorder showed promising results, with many reducing or stopping alcohol use after taking psilocybin. This suggests the treatment is manageable for many.

In tests for depression, a single 25 mg dose of psilocybin significantly reduced depression scores. Although there were some safety concerns, the treatment was still considered tolerable for most participants.

Unlike traditional treatments for depression and addiction, which often rely on antidepressants or behavioral therapy, psilocybin offers a novel approach by using a naturally occurring psychedelic compound. Psilocybin works by targeting serotonin receptors in the brain, potentially leading to profound changes in mood and perception with just a single dose. This rapid action contrasts with many current treatments that require weeks to show benefits. Researchers are particularly excited about its potential to provide long-lasting effects with minimal doses, offering hope for more effective and efficient management of these challenging conditions.

Research has shown that therapy using psilocybin, a compound found in certain mushrooms, can significantly reduce symptoms of depression and substance use disorder (SUD). One study found that a single dose of psilocybin, combined with psychological support, quickly reduced depression symptoms within eight days. Another study discovered that psilocybin helped 67% of participants remain free from depression for at least five years. Additionally, psilocybin-assisted therapy has produced positive results for individuals dealing with addiction, improving their symptoms in several clinical trials. These findings suggest that psilocybin may be an effective treatment for both depression and SUD. Participants in this trial will receive varying doses of psilocybin to further explore its potential benefits.²³⁵⁶⁷